Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
 Blood, 20 August 2009, Vol. 114, No. 8, pp. 1469-1476.
Prepublished online as a Blood First Edition Paper on June 25, 2009; DOI 10.1182/blood-2009-02-179739.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
blood-2009-02-179739v1
114/8/1469    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Google Scholar
Right arrow Articles by Ghielmini, M.
Right arrow Articles by Zucca, E.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ghielmini, M.
Right arrow Articles by Zucca, E.
Related Collections
Right arrow How I Treat
Right arrow Free Research Articles
Right arrow Lymphoid Neoplasia
Right arrowRelated Articles in Blood Online
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

HOW I TREAT

How I treat mantle cell lymphoma

Michele Ghielmini1, and Emanuele Zucca1

1 Oncology Institute of Southern Switzerland, Bellinzona, Switzerland

Mantle cell lymphoma is included in the World Health Organization classification as distinct lymphoma subtype characterized by the t(11;14)(q13;q32) translocation, which results in overexpression of Cyclin D1. The clinical presentation often includes extranodal involvement, particularly of the bone marrow and gut. The prognosis of patients with mantle cell lymphoma (median overall survival, 3-5 years) is poorest among B-cell lymphoma patients, even though a prospectively difficult to identify subgroup can survive for years with little or no treatment. Conventional chemotherapy is not curative but obtains frequent remissions (60%-90%) which are usually shorter (1-2 years) compared with other lymphoma entities. Very intensive regimens, including autologous and allogeneic stem cell transplantation, seem required to improve the outcome, but with the median age of diagnosis being 60 years or more, such approaches are feasible only in a limited proportion of patients. The possibility of treating patients based on prognostic factors needs to be investigated prospectively.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Related Articles in Blood Online:

Central nervous system prophylaxis in mantle cell lymphoma
Moshe E. Gatt and Sigal Grisaro
Blood 2009 114: 5402-5403. [Full Text] [PDF]

Response: CNS prophylaxis in MCL
Michele Ghielmini and Emanuele Zucca
Blood 2009 114: 5403-5404. [Full Text] [PDF]



This article has been cited by other articles:


Home page
 BloodHome page
M. E. Gatt and S. Grisaro
Central nervous system prophylaxis in mantle cell lymphoma
Blood, December 17, 2009; 114(26): 5402 - 5403.
[Full Text] [PDF]

Home page
 BloodHome page
M. Ghielmini and E. Zucca
Response: CNS prophylaxis in MCL
Blood, December 17, 2009; 114(26): 5403 - 5404.
[Full Text] [PDF]

Home page
 haematolHome page
S. A. Pileri and B. Falini
Mantle cell lymphoma
Haematologica, November 1, 2009; 94(11): 1488 - 1492.
[Full Text] [PDF]


click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020